Omega Diagnositcs develops and sells diagnostic test kits for food intolerance, syphilis, tuberculosis, malaria, autoimmune disease and infectious disease. Omega started life as cash shell Quintessentially English, which joined Aim on 18 March 2004, when it raised £250,000 at 5p (200p post-consolidation) a share. The Omega business reversed into the shell on 19 September 2006. An initial consideration of £1.2m was paid for the business and £1m raised from a placing at 2p (80p post-consolidation) a share. On 30 August 2007, a capital reorganisation led to 40 shares being consolidated into one new share. A second reverse takeover happened on 31 August 2007, when Omega acquired Genesis Diagnostics and Cambridge Nutritional Sciences, which develop test kits for autoimmune disease, infectious disease and food intolerance, for up to £6.7m in cash and shares. Omega raised £2.2m at 30p a share at the time of the reversal.